Overview

Pipeline

Program

Target Pathogen

Phase

ACX-362E 1

Clostridium difficile

Discovery Preclinical Phase 1 Phase 2
Discovery Phase complete
Preclinical Phase in progress

ACX-375C 2

Vancomycin-resistant Enterococcus

Discovery Preclinical Phase 1 Phase 2
Discovery Phase in progress
Preclinical Phase not started
Phase 1 Phase not started
Phase 2 Phase not started

CCP 3

Multiple product candidates for other Gram-positive infections

Discovery Preclinical Phase 1 Phase 2
Discovery Phase in progress
Preclinical Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
  1. ACX362E has been granted QIDP (Qualified Infectious Disease Product) status; Fast Track status to be applied for following IND submission
  2. ACX375C is QIDP and Orphan Drug Status eligible and is planned to be applied for pre-IND and post-IND, respectfully.
  3. Computational Chemistry Project to expand universe of potential DCBG-like Pol IIIC inhibitors

Addressing Difficult to Treat Bacterial Infections

Acurx’s approach to counter the emergence of antibiotic-resistant bacterial infections is to develop new antibiotics that effectively block an entirely new molecular target, DNA polymerase IIIC enzymes. 

Our lead antibiotic product candidate, ACX-362E, targets the treatment of Clostridium difficile Infections (CDI) and our second antibiotic product candidate, ACX-375C, targets the treatment of certain gram-positive bacterial infections including vancomycin-resistant enterococcus (VRE).  Both of these antibiotic product candidates have demonstrated the ability to effectively block DNA polymerase IIIC enzymes in early stage studies.

The CDC (Centers for Disease Control & Prevention) has designated C. difficile as a qualifying pathogen under the GAIN Act as an urgent threat highlighting the need for new antibiotics1 See “Qualified Infectious Disease Product (QIDP) Status by the FDA.” Further, the CDC has designated vancomycin-resistant enterococci as a serious threat level priority for new antibiotic development where, despite current treatment, a significant incidence remains and significant number of deaths occur annually.